Therillume
Eagan, United States
Adrienne Watson, PhD,
Founder & Chief Scientific Officer, Therillume
Vice President, Research & Development, Recombinetics.
Dr. Watson completed her Ph.D. in Molecular, Cellular, Developmental Biology and Genetics at the University of Minnesota under the direction of Dr. David Largaespada where she utilized the Sleeping Beauty transposon system to conduct forward genetic screens in mice to uncover novel cancer genes associated with neuro-ocology indications. She generated several mouse models of Neurofibromatosis Type 1 (NF1) and NF1-related malignancies, elucidating novel genetic pathways, and candidates for targeted cancer therapy. After completing her postdoctoral studies at the University of Minnesota, she joined Recombinetics in 2013, where she has led the development swine models for preclinical drug and device studies and regenerative therapeutics. In 2022 she founded a new clinical neuro-oncology company, Therillume, she focuses on applying gene-editing technology to develop swine models of human diseases, where she has generated a platform to induce glioblastoma (GBM) into immuno-competant swine.